We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Developing World Could Be the New IVD Growth Region

By LabMedica International staff writers
Posted on 18 Oct 2011
The next big growth opportunity in in-vitro diagnostics (IVD) is possibly the developing world where high-temperature and scarce water conditions require rapid easy-to-use IVD tests.

A new report from Kalorama Information (Rockville Pike, MD, USA) by diagnostic market analyst Shara Rosen and diagnostic consulting network president Brendan O’Farrell describes a quarter-billion dollar market in the next five years for tests that can detect infectious diseases such as malaria and TB—but also rarer diseases like leptospirosis and chikungunya.

The incidence of TB, malaria, hepatitis, and, in particular, HIV/AIDS continues to increase, with HIV/AIDS and TB likely to account for the overwhelming majority of deaths from infectious diseases in developing countries by 2020. Shara Rosen commented, “For the past 10-15 years politicians and aid agencies have come to understand that infectious diseases are not merely causes of suffering and death but also significant barriers to economic development.”

Increased funding for infectious disease diagnostics by groups such as the Bill and Melinda Gates Foundation, the Program for Appropriate Technology in Health (PATH; Seattle, WA, USA) and The Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland) is helping to develop a new generation of sophisticated test platforms that are designed to meet the needs of low resource environments.

The response of the international community towards the problem has created a market. The report cites a 13% growth rate for sales of point-of-care (POC) tests that treat these most pressing health needs. This is greater than Kalorama forecasts for most areas of the POC diagnostics market.

Shara Rosen added, “There is a huge need for user-friendly, highly specific and reliable technologies for rural and underserved communities worldwide, and that is where the opportunity lies.”

There are at least 75 vendors worldwide that market rapid test kits for emerging infectious diseases. The current market leaders are companies that have invested in sophisticated new technologies and those that have established relationships with governments and international aid agencies.

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:
Kalorama Information
Bill and Melinda Gates Foundation
The Foundation for Innovative New Diagnostics


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests